Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status
Authors:
- Danielle CastilloDCDanielle Castillo
- Tze-An YuanTYTze-An Yuan
- Bita NehorayBNBita Nehoray
- Aleck CervantesACAleck Cervantes
- Kevin K. TsangKTKevin K. Tsang
- Kai YangKYKai Yang
- Sharon R. SandSSSharon R. Sand
- Janet MokhnatkinJMJanet Mokhnatkin
- Josef HerzogJHJosef Herzog
- Thomas P. SlavinTSThomas P. Slavin
- Sophie HymanSHSophie Hyman
- Alison SchwartzASAlison Schwartz
- 2 June 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 31 (8) , 1621-1629
Abstract
Background: Though germline TP53 pathogenic/likely pathogenic variants (PV) are associated with Li–Fraumeni syndrome, many detected by multigene panels represent aberrant clonal expansion (ACE), most due to clonal hematopoiesis (CH). Discerning ACE/CH from germline variants and postzygotic mosaicism (PZM) is critically needed for risk assessment and management. Methods: Participants in the Li-Fraumeni & TP53 Understanding & Progress (LiFT UP) study with a TP53 PV were eligible. Demographics, personal/family cancer history, and clinical laboratory test reports were obtained. DNA from multiple tissues was analyzed using a custom QIAseq assay (ACE panel) that included TP53 and other CH-associated genes; the ACE panel and eyebrow follicles were assessed in a workflow to discern TP53 PV clinical categories. Results: Among 134 participants there was a significant difference for the age at diagnosis (P < 0.001), component cancers (P = 0.007), and clinical testing criteria (P < 0.001), comparing germline with PZM or ACE. ACE panel analysis of DNA from 55 sets of eyebrow follicles (mean 1.4 ug) and 36 formalin-fixed, paraffin imbedded tissues demonstrated low variance (SE, 3%; P = 0.993) for TP53 variant allele fraction, with no significant difference (P = 0.965) between tissue types, and detected CH gene PVs. Of 55 multi-tissue cases, germline status was confirmed for 20, PZM in seven, ACE for 25, and three were indeterminate. Additional CH variants were detected in six ACE and two germline cases. Conclusions: We demonstrated an effective approach and tools for discerning germline TP53 status. Impact: Discernment of PZM and TP53-driven CH increases diagnostic accuracy and enables risk-appropriate care.Keywords
All Related Versions
Funding Information
- NIH (R01 CA242218, RC4 CA153828)
- NIH Cancer Center Support Grant (P30 CA033572)
- Breast Cancer Research Foundation (grant nos.20–172)
This publication has 39 references indexed in Scilit:
- Revisiting Li-Fraumeni Syndrome From TP53 Mutation CarriersJournal of Clinical Oncology, 2015
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA SequenceNew England Journal of Medicine, 2014
- Age-Related Clonal Hematopoiesis Associated with Adverse OutcomesNew England Journal of Medicine, 2014
- Li-Fraumeni syndrome: cancer risk assessment and clinical managementNature Reviews Clinical Oncology, 2014
- Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortiumCancer Genetics, 2012
- 2009 Version of the Chompret Criteria for Li Fraumeni SyndromeJournal of Clinical Oncology, 2009
- Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline MutationsJournal of Clinical Oncology, 2009
- Evaluation of three methods for effective extraction of DNA from human hairJournal of Chromatography B, 2005
- Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.Proceedings of the National Academy of Sciences, 1992
- Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other NeoplasmsScience, 1990